Sucampo Pharmaceuticals
Manufacturing · Ireland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
College Business & Technology Park Cruis...Phone Number
(301) 961-3400Website
www.sucampo.comRevenue
$247.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The companys marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) inRead more
Sucampo Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sucampo Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Sucampo Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Sucampo Pharmaceuticals
Product Launch: Get notified when Sucampo Pharmaceuticals launches new products
Click to see if Sucampo Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Sucampo Pharmaceuticals has new funding data
Check out if Sucampo Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Sucampo Pharmaceuticals recently announced quarterly report
Sucampo Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Sucampo Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Sucampo Pharmaceuticals
Compare insights from companies similar to Sucampo Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sucampo Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sucampo Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sucampo Pharmaceuticals.
Sucampo Pharmaceuticals financials insights
Gather financial insights about Sucampo Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Stock Offering
$43.1M
2015
Debt
$250M
Sucampo Pharmaceuticals Tech Stack
A closer look at the technologies used by Sucampo Pharmaceuticals
Sucampo Pharmaceuticals News & Media
Boyd Gaming Set to Join S&P MidCap 400; Ring Energy, James River Group Holdings and EVERTEC to Join S&P SmallCap 600
NEW YORK, Feb. 6, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: S&P SmallCap 600 constituent Boyd Gaming Corp. (NYSE:BYD) will replace CalAtlantic Group Inc. (NYSE:CAA) in the S&P MidCap...Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc
NEW YORK, Jan. 2, 2018 /PRNewswire/ -- Wolf Popper LLP is investigating claims on behalf of investors in Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), concerning the proposed acquisition of Sucampo by Mallinckrodt plc (NYSE: MNK). Under the terms of the proposed acquisition, Sucampo's...Wired News - Mallinckrodt to Acquire Sucampo Pharmaceuticals
Stock Monitor: Sucampo Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 28, 2017 / Active-Investors.com has just released a free research report on Mallinckrodt PLC (NYSE: MNK). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MNK as the Company's latest news hit the wire. On December 26, 2017, the Company, a leading global specialty pharmaceutical organization, entered into an agrMallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
-- Immediately accretive transaction includes development and commercial assets including AMITIZA® (lubiprostone), a leading product in branded constipation market -- -- Mallinckrodt expects accretion to 2018 adjusted diluted earnings per share of at least $0.30; and at least double that in 2019, assuming expected first quarter 2018 close -- -- Mallinckrodt to commence cash tender offer for $18.00 per share, with support from key Sucampo shareholders -- STAINES-UPON-THAMES, United Kingdom and RO
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Sucampo Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The companys marketed product includes AMITIZA (... Read More
